ENTITY
Jiangxi Boya Bio Pharmaceutical

Jiangxi Boya Bio Pharmaceutical (300294 CH)

13
Analysis
Health Care • China
Jiangxi Boya Bio-Pharmaceutical company Limited develops, produces and sells blood product. The Company's main products include human serum albumin, intravenous immunoglobulin (static C) and fibrinogen.
more
•20 Mar 2025 14:04

Quiddity Leaderboard ChiNext & ChiNext 50 Jun25: US$1.4bn Total One-Way Flows; Basket Trade Idea

There could be ~US$1.1bn and ~US$300mn one-way flows for ChiNext and ChiNext 50 respectively. There is one change in the expected ADDs/DELs for...

Share
bullish•Ruijie Networks
•16 Jan 2025 15:02

Quiddity Leaderboard ChiNext & ChiNext 50 Jun 25: Great Momentum for the Exp ADDs Vs Exp DELs Trade

The expected ADDs have been sharply outperforming the expected DELs and that could continue over the next few weeks/months.

Share
•17 Nov 2024 09:15

China Healthcare Weekly (Nov.17) - TCM VBP New Updates, CR Boya Completes Acquisition of Green Cross

​New national TCM VBP round begins with mild price reduction. NHSA to expand TCM VBP with less impact on exclusive varieties/innovative injections....

Logo
736 Views
Share
•28 Jul 2024 13:43

China Healthcare Weekly (July.28)- Ascentage Gets "A Big Gift", CR Boya Acquires Green Cross, Weigao

We noticed some positive updates about Ascentage as competitors' products encountered challenges. China Resources Boya acquires Green Cross....

Logo
657 Views
Share
•25 Jan 2024 08:55

Haier Group to Buy $1.8B Stake in Shanghai RAAS from Grifols – A New Chapter Begins

We analyzed the key points/logic behind Haier's decision to acquire Shanghai RAAS from Grifols. Despite potential risks, it is still a wise move...

Logo
984 Views
Share
x